When is Mounjaro on the NHS — and what are your options now?

Where the NHS rollout actually stands right now

NICE approved tirzepatide for NHS use in December 2024 under guideline TA1026. That approval alone didn't open the doors to everyone: NHS England then set a phased commissioning schedule that releases eligibility to progressively wider groups over three years.

The first cohort became available from June 2025. To qualify at that stage, a person needed a BMI of 40 or above, plus four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That combination describes a relatively small proportion of people living with obesity in the UK.

Cohort 2 activated on 23 June 2026. This extended access to adults with a BMI of 35–39.9 who also have four or more of those same conditions. The next phase, expected around March 2027, is planned to include a BMI of 40 or above with three qualifying conditions, broadening access further. Ethnic-background thresholds sit 2.5 kg/m² lower at every stage. Even meeting the BMI and condition thresholds does not guarantee a prescription: every patient must also take part in structured diet and activity support, and GP practices can opt in or out of prescribing under the 2026/27 contract. Availability still varies significantly by area. The full NHS Mounjaro picture covers this in detail, including what wraparound care involves.

What the phasing means for your actual decision

A question our prescribers hear most weeks is some version of: "Can I get Mounjaro on the NHS if I'm not diabetic?" The honest answer is: only if you meet the current cohort's thresholds, your GP practice is participating, and you can access the required lifestyle support programme. For most people asking this in mid-2026, that means a wait, potentially until 2027 or beyond.

That reality shapes the decision clearly. If you meet the current NHS criteria, the NHS route is free and clinically supported, the right starting point. If you don't yet qualify, or your GP practice isn't participating, the choice is between waiting and exploring a private prescription.

Private prescriptions are issued under the same SmPC licence. A prescriber assesses clinical suitability against the licensed criteria: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. No referral, no waiting list, no phasing. It is not the NHS. You pay for the treatment, the prescription and the service. On the question of what private treatment costs in the UK, the context around Eli Lilly's 2025 price increase is worth reading before you compare providers.

The thing that matters most in that comparison isn't price alone. It's whether your prescriber has seen your full health picture and whether the medicine reaching you comes through the licensed UK supply chain. Counterfeit pens are a real and growing problem; the MHRA has publicly warned about fake weight-loss injections sold without a prescription, including a Northampton raid in October 2025 involving counterfeit tirzepatide. If you have been wondering when Mounjaro is back in stock and have been searching across multiple sites as a result, it is especially important to verify any online pharmacy on the GPhC register before placing an order.

How the private route works at a regulated pharmacy

If you decide not to wait for NHS access, a regulated online pharmacy can provide Mounjaro on a private prescription after a clinical assessment. At nume, that means a free consultation reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not a decision algorithm. Identity and weight are verified before any prescription is issued. Repeat orders are each clinically re-reviewed; there is no subscription, no auto-renewal.

Treatment dispatches the same day for consultations approved before midday, Monday to Friday, and arrives the following working day via DPD in plain, unbranded packaging. One transparent price covers the consultation, prescription, medicine and delivery. Nothing is added at checkout.

This is a prescription-only medicine. Clinical suitability is not assumed, it is assessed. Mounjaro isn't appropriate for everyone, and a prescriber's job is to tell you that honestly if it applies to you. You can explore the treatment options or read more about how Mounjaro works before deciding whether a consultation makes sense for your situation. If you're weighing it against other licensed options, the weight-loss treatment overview sets out what's available, including guidance on how to buy Mounjaro tablets safely through a regulated provider. Questions about the clinical team reviewing prescriptions are answered on the clinical team page.